Subscribe to this journal

Advanced Search

Share

Español English

Enter your user name and password

* Required fields

Enter your email address

Latest issue

Reumatología Clínica (English Edition)

Reumatología Clínica (English Edition)

ISSN: 2173-5743

Reumatología Clínica is the official publication of scientific Spanish Society of Rheumatology (SER) and the Mexican College of Rheumatology (CMR). Reumatología Clínica publishes original research papers, editorials, reviews, case reports and pictures. Published studies are primarily clinical and epidemiological research but also basic.

See more

Indexed in:

Medline

See more

Follow us:

Subscribe:

tienda

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

1.3

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

2.4

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

0.402

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

0.503

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Export reference

Share

Share

More article options

Outline

Abstract
Keywords
Resumen
Palabras clave
Introduction

Abstract
Keywords
Resumen
Palabras clave
Introduction
Methods
Study design and panel selection
Systematic literature review
Nominal group meeting
Delphi
Final consensus document
Results
Systematic literature review
R 1. in patients with active ra and inadequate response to mtx, this drug should be continued when starting a tnf inhibitor (le 1a; gr a; ga 100%), abt (le 2a; gr b; ga 100%), or rtx (le 1b-2a; gr b; ga 100%)
R 2.mtx should not be discontinued in patients with active ra and inadequate response to mtx who start il-6 inhibitors (le 1a; gr a; ga 91%)
R 3. mtx should not be discontinued in patients with active ra and inadequate response to mtx who start jaks inhibitors (le 1b; gr a; ga 91%)
R 4. when starting a combined therapy with mtx and bdmards in mtx-inadequate responders ra patients, it is recommended to continue with the same mtx doses (le 1b; gr a; ga 100%)
R 5. when combining mtx with tnf inhibitors, the dose of mtx should be of at least 10 mg/week (le 1b; gr a; ga 100%)
R 6. when starting a combined therapy with mtx and jaks inhibitors in mtx- inadequate responders ra patients, it is recommended to continue with the same mtx doses (le 1b; gr a; ga 100%)
R 7. in ra patients who have achieved and sustained the treatment goal, the panel recommends, as treatment strategy, to give priority to the de-escalation of the bdmards, which does not exclude mtx dose adjustments or even mtx withdrawal in some intolerant patients on il-6 inhibitors (le 5; gr d; ga 100%)
R 8. bdmards should be combined with mtx as the first csdmard choice, although other csdmards could be considered in case of mtx intolerance/contraindication (le 1b; gr a; ga 100%)
R 9. jaks inhibitors should be combined with mtx as the first csdmard choice, although other csdmards could be considered in case of mtx intolerance/contraindication (le 1b; gr a; ga 100%)
R 10. combination therapy of mtx with bdmards and tsdmards does not imply a different management of the standard of care for routine patient safety monitoring (le 5; gr d; ga 100%)
Discussion
Financing
Conflict of interest
Bibliography

Original Article

DOI: 10.1016/j.reumae.2020.08.009

Open Access

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

Documento de expertos sobre el uso de terapia combinada de metotrexato con terapias biológicas o terapias dirigidas a pacientes con artritis reumatoide

Download PDF

Jesús Tornero-Molinaa,

, Mercedes Alperi-Lópezb, Ivan Castellvíc, Juan José de Agustín-de Orod, Alejandro Escuderoe, Rosario García-Vicuñaf, Miguel Ángel González-Gayg, Cristina Hidalgoh, Esteban Rubioi, Raimon Sanmartíj, Núria Casamirak, Jaime Calvo-Alénl

a Servicio de Reumatología, Hospital de Guadalajara, Guadalajara, Spain

b Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain

c Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

d Servicio de Reumatología, Hospital Universitari Valld’Hebron, Barcelona, Spain

e Servicio de Reumatología, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain

f Servicio de Reumatología, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain

g Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain

h Servicio de Reumatología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain

i Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

j Servicio de Reumatología, Hospital Universitari Clínic, Barcelona, Spain

k Departamento Médico, Laboratorios Gebro Pharma, Barcelona, Spain

l Servicio de Reumatología, Hospital Universitario Araba, Vitoria-Gasteiz, Spain

Ver más

Article

This article is available in English

Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

Jesús Tornero-Molina, Mercedes Alperi-López, Ivan Castellví, Juan José de Agustín-de Oro, Alejandro Escudero, Rosario García-Vicuña, Miguel Ángel González-Gay, Cristina Hidalgo, Esteban Rubio, Raimon Sanmartí, Núria Casamira, Jaime Calvo-Alén

10.1016/j.reumae.2020.08.009

Reumatol Clin. 2022;18:33-41

Idiomas

Reumatología Clínica (English Edition)